RDY Stock: Price, Earnings History and SEC Filings
Dr. Reddy's Laboratories Limited (RDY) last traded at $14.17, up 0.43% on the latest session and up 12.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.12 against an analyst estimate of $0.16, a miss of 25.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RDY earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 23, 2026 | $0.12 | $0.16 | -25.00% |
| Jun 2026 | Jul 22, 2026 | $0.06 | $0.17 | -64.71% |
| Mar 2026 | May 12, 2026 | $0.06 | $0.09 | -33.33% |
| Dec 2025 | Jan 21, 2026 | $0.16 | $0.16 | +0.00% |
RDY beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RDY
Insider filing activity
RDY insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RDY news
- Dr. Reddy’s Laboratories Ltd ADROct 30, 2026 · 247wallst.com
- RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallOct 26, 2026 · finance.yahoo.com
- Dr. Reddy's Laboratories Q2 Earnings Call HighlightsOct 23, 2026 · marketbeat.com
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (RDY) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in India. Its fiscal year ends in March.